Local anesthetic improves individuals affected with herpes simplex type 1 labialis

Area of Science:

• Dermatology
• Virology
• Pharmaceutical Sciences

Background:

• Herpes simplex virus 1 (HSV-1) infections, or herpes simplex labialis (HSL), affect approximately 40% of the global population, significantly impacting patient quality of life.
• There is a continuous need for effective therapeutic alternatives to manage HSV-1 infections and their associated complications.

Purpose of the Study:

• To evaluate the therapeutic efficacy of an innovative in situ film precursor semisolid composition for treating herpes simplex lesions caused by HSV-1 in humans.
• To assess the clinical benefits, convenience, and healing time of the novel composition compared to existing treatments.

Main Methods:

• Eighty-one patients diagnosed with HSV-1 were enrolled in the study.
• The in situ film precursor semisolid composition was applied three times within a 24-hour period (T0, T8, T16).
• Clinical assessments, including photographic documentation, were conducted at baseline, 24 hours, and 72 hours post-application, with a 6-month and 1-year follow-up.

Main Results:

• Frequency analysis revealed that 40.3% of patients experienced symptom remission within 24 hours after the final application.
• The film precursor demonstrated significant therapeutic potential and offered an aesthetic advantage over conventional ointments and gels.
• The treatment regimen involved convenient dosing with only three applications in 24 hours.

Conclusions:

• The in situ film precursor semisolid composition shows promise as an effective treatment for herpes simplex lesions.
• This novel formulation offers advantages in terms of dosage convenience, aesthetic appeal, and potentially lower production costs.
• The observed healing times were notably shorter than those reported for topical antiretroviral therapies, suggesting a significant advancement in HSL management.